Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 493-501

  Honda, Hirokazu ^a   Ueda, Masashi ^b   Kojima, Shiho ^b   Mashiba, Shinichi ^b   Michihata, Tetsuo ^c   Takahashi, Keiko ^d   Shishido, Kanji ^d   Akizawa, Tadao ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ikagaku Co Ltd   (Japan)

^c Department of Dialysis   (Japan)

^d Kawasaki Clinic   (Japan)

Author keywords

Cardiovascular disease; Interleukin 6; Oxidized high density lipoprotein

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MYELOPEROXIDASE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GERIATRIC NUTRITIONAL RISK INDEX; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; OXIDATION KINETICS; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN ENERGY WASTING; RISK FACTOR;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHI-SQUARE DISTRIBUTION; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INTERLEUKIN-6; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION ASSESSMENT; NUTRITIONAL STATUS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84855982490     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.038     Document Type: Article

References (32)

1. Tabet F., Rye K.A., High-density lipoproteins, inflammation and oxidative stress Clin Sci (Lond) 2009, 116:87-98.
2. Florentin M., Liberopoulos E.N., Wierzbicki A.S., et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008, 23:370-378.
3. Francis G.A. The complexity of HDL. Biochim Biophys Acta 2010, 1801:1286-1293.
4. Assinger A., Koller F., Schmid W., et al. Specific binding of hypochlorite-oxidized HDL to platelet CD36 triggers proinflammatory and procoagulant effects. Atherosclerosis 2010, 212:153-160.
5. Vaziri N.D., Navab M., Fogelman A.M. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 2010, 6:287-296.
6. Navab M., Reddy S., Van Lenten B.J., et al. Role of dysfunctional HDL in atherosclerosis. J Lipid Res 2008, 50:S145-S149.
7. Navab K.D., Elboudwarej O., Gharif M., et al. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease. Curr Pharm Des 2011, 17:17-20.
8. Toth P.P., Davidson M.H. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol. 2010, 4:359-364.
9. Heinecke J. HDL and cardiovascular-disease risk-time for a new approach?. N Engl J Med 2011, 364:170-171.
10. Kalantar-Zadeh K., Kopple J.D., Kamranpour N., et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007, 72:1149-1156.
11. Honda H., Ueda M., Kojima S., et al. Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:1021-1028.
12. Stenvinkel P., Heimbürger O., Lindholm B., et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000, 15:953-960.
13. Honda H., Qureshi A.R., Heimbüger O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006, 47:139-148.
14. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003, 41(I-IV):S1-S91. Group KDOQIKD.
15. Yamada K., Furuya R., Takita T., et al. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr 2008, 87:106-113.
16. Clinical practice guidelines for nutrition in chronic renal failure K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000, 35:S1-S140.
17. Honda H., Ueda M., Kojima S., et al. Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol 2009, 4:142-151.
18. Prontera C., Emdin M., Zucchelli G.C., et al. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004, 42:37-44.
19. Ueda M., Hayase Y., Mashiba S. Establishment and evaluation of 2 monoclonal antibodies against oxidized apolipoprotein A-I (apoA-I) and its application to determine blood oxidized apoA-I levels. Clin Chim Acta 2007, 378:105-111.
20. Navab M., Anantharamaiah G.M., Reddy S.T., et al. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009, 58:2711-2717.
21. Navab M., Reddy S.T., Van Lenten B.J., et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 201:222-232.
22. Toth P.P., Davidson M.H. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol 2010, 4:359-364.
23. Smith J.D. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010, 30:151-155.
24. McMahon M., Grossman J., Skaggs B., et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009, 60:2428-2437.
25. Panichi V., Rizza G.M., Paoletti S., et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008, 23:2337-2343.
26. Zoccali C., Tripepi G., Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients?. J Am Soc Nephrol 2006, 17:S169-S173.
27. Panichi V., Maggiore U., Taccola D., et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1154-1160.
28. Stenvinkel P., Heimbürger O., Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002, 39:274-282.
29. Kato A., Odamaki M., Takita T., et al. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 2002, 61:1143-1152.
30. Dodani S., Kaur R., Reddy S., et al. Can dysfunctional HDL explain high coronary artery disease risk in South Asians?. Int J Cardiol 2008, 129:125-132.
31. van Leuven S.I., Hezemans R., Levels J.H., et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007, 48:2640-2646.
32. Tsirpanlis G., Bagos P., Ioannou D., et al. The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant 2004, 19:150-157.